Madhava Balakrishna Mallia

Madhava Balakrishna Mallia

Auto-generated profile, based on publicly available information

Madhava Balakrishna Mallia

Radiopharmaceuticals Division Bhabha Atomic Research Centre, Trombay Mumbai India

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 June 2020 in Biomacromolecules
Verified
Journal Article
Closed access
BBBiji Balakrishnan
Biji Balakrishnan
SSSuresh Subramanian
Suresh Subramanian
MMMadhava B. Mallia
Madhava B. Mallia
KRKrishnamohan Repaka
Krishnamohan Repaka
SKShahdeep Kaur
Shahdeep Kaur
RBRinti Banerjee
Rinti Banerjee

20 June 2023 in Bioorganic Chemistry
Verified
Journal Article
Closed access
SMSweety Mittal
Sweety Mittal
MMMadhava B. Mallia
Madhava B. Mallia

3 April 2017 in ChemistrySelect
Verified
Journal Article
Closed access
PDF file
KVKusum Vats
Kusum Vats
MMMadhava B. Mallia
Madhava B. Mallia
AMAnupam Mathur
Anupam Mathur
HSHaladhar D. Sarma
Haladhar D. Sarma
SBSharmila Banerjee
Sharmila Banerjee

1 May 2016 in Cancer Biotherapy and Radiopharmaceuticals
Verified
Journal Article
Closed access
MMMadhava B. Mallia
Madhava B. Mallia
ASAjit Sugunan Shinto
Ajit Sugunan Shinto
MKMythili Kameswaran
Mythili Kameswaran
KKKoramadai Karuppusamy Kamaleshwaran
Koramadai Karuppusamy Kamaleshwaran
RKRadhakrishnan Kalarikal
Radhakrishnan Kalarikal
SBSharmila Banerjee
Sharmila Banerjee
188Re-HEDP is an established radiopharmaceutical used for pain palliation in patients with osseous metastasis. Considering commercial availability of 188W/188Re generator, the accessibility to a lyophilized kit would make preparation of this radiopharmaceutical feasible at the hospital radiopharmacy having access to a generator. A protocol for the preparation of a single-vial lyophilized hydroxyethane 1,1-diphosphonic acid (HEDP) kit was developed and its consistency was checked by preparing six batches. Each sterile lyophilized kit prepared as per the protocol contained 9 mg of HEDP, 3 mg of gentisic acid, and 4 mg of SnCl2.2H2O. Randomly selected kits from all six batches were subjected to thorough quality control tests that were passed by all batches. 188Re-HEDP could be prepared by addition of 1 mL of freshly eluted Na188ReO4 (up to 3700 MBq) containing 1 μmol of carrier ReO4− (perrhenate) and heating at 100°C for 15 minutes. 188Re-HEDP with >95% radiochemical purity could be consistently prepared using the lyophilized kits. Sterile 188Re-HEDP prepared using the lyophilized kit was evaluated in patients with osseous metastasis. Post-therapy images of the patient were compared with 99mTc-MDP bone scan and found to be satisfactory. The bone-to-background as well as tumor-to-normal bone uptake ratio was found to be significant. All patients who received therapy reported significant pain relief within a week to 10 days post-administration of 188Re-HEDP.

1 July 2018 in Applied Radiation and Isotopes
Verified
Journal Article
Closed access
MMMadhava B. Mallia
Madhava B. Mallia
VCViju Chirayil
Viju Chirayil
ADAshutosh Dash
Ashutosh Dash

27 January 2022 in Materials Advances
Verified
Journal Article
Open access
PDF file
SMSweety Mittal
Sweety Mittal
RSRohit Sharma
Rohit Sharma
HSHaladhar D. Sarma
Haladhar D. Sarma
MMMadhava B. Mallia
Madhava B. Mallia
Theranostic 177Lu-labeled nitroimidazole-decorated gold nanoparticles showed ∼9-fold uptake in CHO cells under hypoxic conditions compared to normoxic conditions.